Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
Open Access
- 31 October 2022
- journal article
- research article
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 2022, 1-5
Abstract
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( ). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.Keywords
This publication has 27 references indexed in Scilit:
- Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancerDiagnostic Cytopathology, 2010
- Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010Thorax, 2010
- Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?The Oncologist, 2009
- Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor massInternational Journal of Cardiology, 2008
- Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future DirectionsThe Oncologist, 2008
- The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecologic Oncology, 2006
- Vascular endothelial growth factor in pleural effusions of different originEuropean Respiratory Journal, 2005
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal of Cancer, 1993